Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pradip K Majumder

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Oncogene|November 17, 2005
Akt-regulated pathways in prostate cancerPradip K Majumder, William R Sellers
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2007
Identification of prostate cancer modifier pathways using parental strain expression mappingQing Xu, Pradip K Majumder, Kenneth Ross, et al.
Nature Communications|February 12, 2015
Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transitionAaron Goldman, Biswanath Majumder, Andrew Dhawan, et al.
Journal of Cell Communication and Signaling|September 5, 2022
Lupeol and Paclitaxel cooperate in hindering hypoxia induced vasculogenic mimicry via suppression of HIF-1α-EphA2-Laminin-5γ2 network in human oral cancerDepanwita Saha, Debarpan Mitra, Neyaz Alam, et al.
Cancer Cell|January 11, 2011
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activitySarat Chandarlapaty, Ayana Sawai, Maurizio Scaltriti, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 18, 2006
Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytesHiranmoy Das, Ajay Kumar, Zhiyong Lin, et al.
Blood|February 28, 2009
Targeting the Notch1 and mTOR pathways in a mouse T-ALL modelKathleen Cullion, Kyle M Draheim, Nicole Hermance, et al.
Molecular Cancer Therapeutics|June 24, 2010
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivoHiroshi Hirai, Hiroshi Sootome, Yoko Nakatsuru, et al.
Nature Nanotechnology|November 19, 2021
Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cellsTanmoy Saha, Chinmayee Dash, Ruparoshni Jayabalan, et al.
Cellular Oncology (Dordrecht, Netherlands)|January 1, 2017
CDKN2A-p53 mediated antitumor effect of Lupeol in head and neck cancerSayantan Bhattacharyya, Vasanthakumar Sekar, Biswanath Majumder, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Oncogene|November 17, 2005
Akt-regulated pathways in prostate cancerPradip K Majumder, William R Sellers
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2007
Identification of prostate cancer modifier pathways using parental strain expression mappingQing Xu, Pradip K Majumder, Kenneth Ross, et al.
Nature Communications|February 12, 2015
Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transitionAaron Goldman, Biswanath Majumder, Andrew Dhawan, et al.
Journal of Cell Communication and Signaling|September 5, 2022
Lupeol and Paclitaxel cooperate in hindering hypoxia induced vasculogenic mimicry via suppression of HIF-1α-EphA2-Laminin-5γ2 network in human oral cancerDepanwita Saha, Debarpan Mitra, Neyaz Alam, et al.
Cancer Cell|January 11, 2011
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activitySarat Chandarlapaty, Ayana Sawai, Maurizio Scaltriti, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 18, 2006
Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytesHiranmoy Das, Ajay Kumar, Zhiyong Lin, et al.
Blood|February 28, 2009
Targeting the Notch1 and mTOR pathways in a mouse T-ALL modelKathleen Cullion, Kyle M Draheim, Nicole Hermance, et al.
Molecular Cancer Therapeutics|June 24, 2010
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivoHiroshi Hirai, Hiroshi Sootome, Yoko Nakatsuru, et al.
Nature Nanotechnology|November 19, 2021
Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cellsTanmoy Saha, Chinmayee Dash, Ruparoshni Jayabalan, et al.
Cellular Oncology (Dordrecht, Netherlands)|January 1, 2017
CDKN2A-p53 mediated antitumor effect of Lupeol in head and neck cancerSayantan Bhattacharyya, Vasanthakumar Sekar, Biswanath Majumder, et al.
Pageof 3